Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Summary

This is a phase 2a, open-label, multicenter study investigating the safety, tolerability, and antiviral activity of durvalumab administered at targeted times during a 48-week treatment period of imdusiran in virologically-suppressed CHB subjects

Timeline

Start

2024-05-01

Primary completion

2024-08-01

Completion

2024-08-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications